MOH
Molina Healthcare, Inc.NYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Wed, Nov. 9, 8:29 AM
    • Hospital groups look a bit sickly premarket as investors appear to perceive a less-than-robust future under a Trump presidency.
    • Sampling: (NYSE:HUM-2%; (NYSE:HCA-16%; (NYSE:THC-26%; (NYSE:CYH-18%; (NYSE:UHS-10%; (NYSE:SEM-7%; (NASDAQ:LPNT-12%
    • Healthcare services are weak as well: (NYSE:UNH-3%; (NYSE:MOH-8%; (NASDAQ:AMSG-11%; (NASDAQ:AMED-3%; (NYSE:EVHC-5%
    | Wed, Nov. 9, 8:29 AM | 31 Comments
  • Wed, Nov. 9, 3:03 AM
    • Healthcare stocks, the weakest sector this year, may become winners, as Obamacare reforms are set to be "repealed and replaced" and major legislation Clinton proposed is unlikely to be imposed on drugmakers.
    • While Trump hasn't set out a comprehensive alternative to the Affordable Care Act (which may see 22M Americans lose current coverage), he said he'll encourage competition between markets in different states.
    • Insurance stocks: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    • Drugmakers premarket: MYL +5.8%, NVS +3.4%, SNY +2.9%, AZN +2.4%, GSK +1.9%, PFE +1.8%, CELG +1%, ABBV, MRK, BMY, LLY, JNJ, ABT, ACET, ZTS, BIIB, REGN
    • #Election2016
    | Wed, Nov. 9, 3:03 AM | 14 Comments
  • Thu, Oct. 27, 4:24 PM
    • Molina Healthcare (NYSE:MOH): Q3 EPS of $0.85 beats by $0.09.
    • Revenue of $4.55B (+26.0% Y/Y) beats by $180M.
    • Press Release
    | Thu, Oct. 27, 4:24 PM
  • Thu, Oct. 27, 3:41 AM
    • Not only are Obamacare premiums on the rise for 2017, deductibles will also be getting more expensive, according to an analysis by insurance comparison site HealthPocket.
    • Deductibles for individuals enrolled in the lowest-priced Obamacare health plans will average more than $6,000 next year, the first time that threshold has been cracked in the three years that Affordable Care Act marketplaces have been in business. Families enrolled in the bronze plans will average deductibles of $12,393.
    • Previously: Obamacare rates up 25% in 2017 (Oct. 25 2016)
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    | Thu, Oct. 27, 3:41 AM | 42 Comments
  • Wed, Oct. 26, 5:35 PM
  • Tue, Oct. 25, 2:22 AM
    • The average premium for benchmark 2017 Obamacare insurance plans sold on Healthcare.gov will jump 25% to $302 compared to this year, the biggest increase since the insurance first went on sale in 2013.
    • Seeking to downplay the cost hikes, the administration said that including subsidies 77% of people would be able to find insurance plans with monthly premiums below $100, however, one in five consumers will only have one insurer from which to choose coverage.
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    | Tue, Oct. 25, 2:22 AM | 43 Comments
  • Fri, Sep. 23, 8:28 AM
    • Clovis Oncology (NASDAQ:CLVS) upgraded to Outperform from Neutral by Credit Suisse. Price target raised to $41 (7% upside) from $19.
    • Sarepta Therapeutics (NASDAQ:SRPT) upgraded to Outperform from Market Perform with a $64 (5% upside) price target by Cowen and Company. Upgraded to Hold from Underperform with a $50 (18% downside risk) price target by Jefferies. Upgraded to Outperform from Market Perform with an $88 (44% upside) price target by William Blair. Upgraded to Neutral from Reduce by SunTrust Banks. Price target raised to $48 (21% downside risk) from $4. Upgraded to Market Perform from Underperform with a $50 (18% downside risk) price target by Leerink Swann. Upgraded to Buy from Neutral by Janney Montgomery Scott. Price target raised to $65 (7% upside) from $30.
    • Molina Healthcare (NYSE:MOH) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $58 (2% downside risk) from $51.
    • Tobira Therapeutics (NASDAQ:TBRA) downgraded to Hold from Buy by Cantor Fitzgerald. Price target raised to $42 (6% upside) from $19.
    • OraSure Technologies (NASDAQ:OSUR) downgraded to Neutral from Buy by BTIG Research. $8 price target removed.
    | Fri, Sep. 23, 8:28 AM | 3 Comments
  • Mon, Aug. 29, 1:38 AM
    • According to an analysis by the Kaiser Family Foundation, nearly a third of U.S. counties will likely be served by only one insurer that participates in an Affordable Care Act marketplace in 2017, representing an increase from 7% this year.
    • The data underscores the degree to which industry retrenchment from low enrollment and high service costs is curtailing options within the marketplaces.
    • Insurer departures will likely lead to higher prices, analysts have warned.
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    | Mon, Aug. 29, 1:38 AM | 19 Comments
  • Wed, Jul. 27, 4:24 PM
    • Molina Healthcare (NYSE:MOH): Q2 EPS of $0.67 beats by $0.18.
    • Revenue of $4.36B (+23.9% Y/Y) beats by $10M.
    • Press Release
    | Wed, Jul. 27, 4:24 PM | 1 Comment
  • Tue, Jul. 26, 5:35 PM
  • Tue, May 24, 9:38 AM
    • Worried about Fed rate hikes pushing the greenback up higher? Focus on growing companies deriving at least 80% of sales from the U.S., says Jefferies' Steven DeSanctis.
    • He notes the dollar peaked on Jan. 20, and sectors with big overseas exposure have outperformed since. However, with higher interest rates looking like they might send the dollar back into an uptrend, it's time to refocus on companies less reliant on exports.
    • DeSanctis and team identified 27 small- and mid-cap companies that were: In the Russell 2500 and Buy-rated by Jefferies, have less than 20% of sales outside of U.S., "sit in the highest two quintiles" based on ROE, and have market values north of $2B.
    • Of that group, they picked ten showing the highest growth of sales per share (though a tie brought the total to 11): Paycom Software (NYSE:PAYC), Lithia Motors (NYSE:LAD), Centene Corp. (NYSE:CNC), Molina Healthcare (NYSE:MOH), Five Below (NASDAQ:FIVE), Mednax (NYSE:MD), Western Alliance Bancorp (NYSE:WAL), Signature Bank (NASDAQ:SBNY), KAR Auction (NYSE:KAR), Science Applications (NYSE:SAIC), and Urban Outfitters (NASDAQ:URBN).
    | Tue, May 24, 9:38 AM | 6 Comments
  • Fri, May 6, 10:32 AM
    • Baxter International (BAX -1.1%) initiated with Buy rating and $51 (13% upside) price target by Evercore ISI.
    • Intrexon (XON +2.3%) initiated with Market Outperform rating and $42 (62% upside) price target by JMP Securities.
    • Heron Therapeutics (HRTX -8.8%) initiated with Buy rating and $41 (143% upside) price target by Cantor Fitzgerald.
    • Dr. Reddy's Laboratories (RDY -2.5%) initiated with Neutral rating and Rs.3,334 price target (8% upside) by Goldman Sachs.
    • Aeglea BioTherapeutics (AGLE +7.4%) initiated with Buy rating and $12 (33% upside) price target by UBS.
    • Cardiome (CRME +34.9%) upgraded to Speculative Buy from Hold by Mackie Research. Price target raised to $8.60 (58% upside) from $5.20.
    • Medivation (MDVN +1.2%) upgraded to Buy from Neutral by Citigroup. Price target raised to $73 (22% upside) from $37.
    • Masimo (MASI -0.3%) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $52 (13% upside) from $43.
    • GlaxoSmithKline (GSK -1%) upgraded to Buy from Reduce by Oddo & Cie.
    • Cogentix Medical (CGNT -1%) downgraded to Neutral from Buy with a price target of $1.15 (14% upside) by Roth Capital.
    • Bruker (BRKR +0.8%) downgraded to Neutral from Outperform by BTIG Research.
    • Relypsa (RLYP -4%) downgraded to Underperform from Neutral by Mizuho Securities. Price target cut to $31 (132% upside) from $34.
    • Molina Healthcare (MOH -0.7%) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $45 (0% upside) from $75. Downgraded to Neutral from Buy by UBS. Price target lowered to $54 (20% upside) from $76.
    • Sarepta Therapeutics (SRPT +1.8%) downgraded to Underperform from Market Perform by Leerink Swann. Price target lowered to $5 (71% downside risk) from $13.
    • Sanofi (SNY -0.4%) downgraded to Hold from Buy with an €81 (15% upside) price target by HSBC.
    | Fri, May 6, 10:32 AM | 4 Comments
  • Fri, Apr. 29, 4:12 PM
    • Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
    • Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
    • Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
    • Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
    • Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
    • ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
    • Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
    • Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
    • Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
    • Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
    • Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
    • St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
    • Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
    • Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
    • Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
    • Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
    • Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
    | Fri, Apr. 29, 4:12 PM | 5 Comments
  • Fri, Apr. 29, 12:44 PM
    | Fri, Apr. 29, 12:44 PM
  • Fri, Apr. 29, 9:12 AM
    | Fri, Apr. 29, 9:12 AM | 9 Comments
  • Fri, Apr. 29, 8:49 AM
    • Molina Healthcare (NYSE:MOH) Q1 results ($M): Total Revenues: 4,343 (+37.0%); Medical Care Costs: 3,588 (+36.1%).
    • Net Income: 24 (-14.3%); Non-GAAP Net Income: 29 (-6.5%); EPS: 0.43 (-23.2%); Non-GAAP EPS: 0.51 (-17.7%); CF Ops: 139 (-74.9%).
    • Medical Care Ratio: 89.8% (+1.2%).
    • 2016 Guidance: Revenues: $17.3B - 17.4B; Medical Care Costs: $14.2B; Medical Care Ratio: 88.9 - 89.2%; EPS: $2.15 - 12.60; Non-GAAP EPS: $2.59 - 2.95.
    • Q2 consensus is EPS of $1.02 on revenues of $4.27B.
    • Shares are off 14% premarket on robust volume.
    | Fri, Apr. 29, 8:49 AM